Table 3.
Clinical and demographic features of the 17 patients with COVID-19 vaccination-unrelated Guillain-Barrè syndrome.
| Pt # | Sex, Age (years) | Antecedent events | GBS subtype | Therapy | TRF | Cranial Nerves | Ataxia | Dysautonomia | Respiratory failure | Months to last follow-up visit | GSB-DS (T0 vsT1) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F, 32 | Influenza vaccination | AIDP | IVIg | No | No | No | No | No | 3 months | 2; 1 |
| 2 | M, 55 | Campylobacter Jejuni infection | AMAN | PEX, IVIg | No | Bifacial paresis, dysphagia, dysphonia | No | Hypotension | Yes | 6 months | 5; 6 |
| 3 | M, 57 | None | AIDP | PEX, IVIg, | No | Bifacial paresis | No | No | Yes | 1 month | 5; 6 |
| 4 | F, 80 | Fever | AIDP | PEX | No | No | Yes | No | No | 14 months | 2; 1 |
| 5 | F, 28 | CMV infection | normal ENG | IVIg | No | Bifacial paresis, perioral myokymies | No | No | No | 5 months | 1; 1 |
| 6 | F, 62 | None | AMSAN | PEX | No | Left 3rd nerve paresis, dysphonia, dysphagia | No | Acute urinary retention | Yes | 1 month | 5; 6 |
| 7 | F,70 | Bronchitis | AMSAN | IVIg | No | No | No | Acute urinary retention | Yes | 12 months | 3; 2 |
| 8 | M, 58 | None | AIDP | IVIg | No | No | No | No | No | 4 months | 4; 3 |
| 9 | M, 52 | SARS-CoV-2 | AMAN | PEX, IVIg | No | Bifacial & left 6th nerve paresis | No | No | Yes | 12 months | 5; 3 |
| 10 | M, 91 | Gastroenteritis | AMAN | IVIg | No | No | No | No | No | 5 months | 4; 1 |
| 11 | M, 80 | Pneumonia | AMAN | IVIg | No | No | No | No | Yes | NA | 5; NA |
| 12 | M, 59 | Gastroenteritis | AMSAN | IVIg | No | 5th nerve paresis, dysphagia, dysphonia | No | No | Yes | 5 months | 5; 1 |
| 13 | M, 74 | SARS-CoV-2 | AMSAN | IVIg | No | No | No | No | No | 10 months | 4; 0 |
| 14 | M, 75 | None | AIDP | IVIg | Yes | No | Yes | No | No | 2 months | 2; 2 |
| 15 | M, 86 | Gastroenteritis | AMSAN | IVIg | No | No | No | No | No | 5 months | 4; 0 |
| 16 | M, 45 | None | AIDP | IVIg | No | Bifacial paresis | Yes | No | No | 2 months | 2; 1 |
| 17 | M, 74 | None | AIDP | PEX | No | No | Yes | No | No | 3 months | 4; 1 |
AIDP, Acute Inflammatory Demyelinating Polyneuropathy; AMAN, Acute Motor Axonal Neuropathy; AMSAN, Acute Motor and Sensory Axonal Neuropathy; CMV, Cytomegalovirus; ENG, electroneurography; GBS, Guillain-Barré syndrome; GBS-DS, Guillain-Barré Syndrome Disability Score; IVIg, intravenous immunoglobulins; NA, not available; PEX, plasma-exchange; Pt, patient; TRF, treatment related fluctuations; T0, first neurological evaluation; T1, last follow-up neurological evaluation.